- Home
- AEMD vs CHRO Comparison
AEMD vs CHRO Comparison
Compare AEMD & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- CHRO
- Stock Information
- Founded
- AEMD 1984
- CHRO 2002
- Country
- AEMD United States
- CHRO United States
- Employees
- AEMD N/A
- CHRO N/A
- Industry
- AEMD Medical/Dental Instruments
- CHRO
- Sector
- AEMD Health Care
- CHRO
- Exchange
- AEMD Nasdaq
- CHRO Nasdaq
- Market Cap
- AEMD 7.3M
- CHRO 8.1M
- IPO Year
- AEMD N/A
- CHRO 2024
- Fundamental
- Price
- AEMD $0.38
- CHRO $1.30
- Analyst Decision
- AEMD Strong Buy
- CHRO Strong Buy
- Analyst Count
- AEMD 1
- CHRO 1
- Target Price
- AEMD $7.00
- CHRO N/A
- AVG Volume (30 Days)
- AEMD 89.6K
- CHRO 2.1M
- Earning Date
- AEMD 02-12-2025
- CHRO 05-14-2025
- Dividend Yield
- AEMD N/A
- CHRO N/A
- EPS Growth
- AEMD N/A
- CHRO N/A
- EPS
- AEMD N/A
- CHRO N/A
- Revenue
- AEMD N/A
- CHRO N/A
- Revenue This Year
- AEMD N/A
- CHRO N/A
- Revenue Next Year
- AEMD N/A
- CHRO N/A
- P/E Ratio
- AEMD N/A
- CHRO N/A
- Revenue Growth
- AEMD N/A
- CHRO N/A
- 52 Week Low
- AEMD $0.24
- CHRO $0.45
- 52 Week High
- AEMD $1.79
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- AEMD 49.25
- CHRO 45.71
- Support Level
- AEMD $0.35
- CHRO $1.25
- Resistance Level
- AEMD $0.37
- CHRO $1.65
- Average True Range (ATR)
- AEMD 0.03
- CHRO 0.20
- MACD
- AEMD 0.01
- CHRO 0.01
- Stochastic Oscillator
- AEMD 79.31
- CHRO 10.88
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.